OPKO Health’s (OPK) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of OPKO Health (NASDAQ:OPK) in a research report report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $3.00 target price on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Tuesday. Piper Sandler reissued an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday, November 8th.

OPKO Health Price Performance

OPK stock opened at $1.48 on Wednesday. The firm has a 50 day moving average price of $1.54 and a 200-day moving average price of $1.50. OPKO Health has a 52-week low of $0.86 and a 52-week high of $1.76. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -7.79 and a beta of 1.63. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 125,000 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was purchased at an average price of $1.59 per share, with a total value of $198,750.00. Following the transaction, the chief executive officer now directly owns 212,536,477 shares in the company, valued at approximately $337,932,998.43. The trade was a 0.06 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders purchased 1,304,255 shares of company stock valued at $2,024,605. Company insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

Several hedge funds have recently bought and sold shares of OPK. CIBC Asset Management Inc lifted its stake in OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 8,978 shares in the last quarter. FMR LLC lifted its stake in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. Algert Global LLC purchased a new stake in OPKO Health in the 2nd quarter worth $44,000. Orion Portfolio Solutions LLC purchased a new stake in shares of OPKO Health during the 3rd quarter valued at about $45,000. Finally, Private Advisor Group LLC raised its position in shares of OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.